China Aims to Insure 80% of Newborns with Basic Medical Insurance by 2024
The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC), along with three...
March 2024
Novartis Gene Therapy Zolgensma Shows Continued Benefits in Broader SMA Patient Group
Swiss pharmaceutical giant Novartis (NYSE: NVS) has presented Phase III data this week, demonstrating that...
Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases
California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...
Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...
Henlius Biotech Forecasts First-Ever Profit in 2023 Driven by Sales Growth and Efficient Management
Shanghai Henlius Biotech Inc., (HKG: 2696), a China-based biopharmaceutical company, has released a positive profit...
Nuance Pharma Wins Arbitration, Rescinds Licensing Deal with Antibe Therapeutics
Nuance Pharma, a China-based pharmaceutical company, has received a favorable arbitration verdict from a Singapore...
Aosaikang’s Marketing Approval Filing for Delafloxacin Accepted by China’s NMPA
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the...
Vivolight Medical Secures Over RMB 100 Million in Strategic Financing to Boost Global Expansion
Shenzhen Vivolight Medical Device & Technology Co., Ltd, a Chinese medical device company nurtured and...
Huadong Medicine’s Arcalyst Filing for Recurrent Pericarditis Accepted by China’s NMPA
Huadong Medicine Co., Ltd, (SHE: 000963) a Chinese pharmaceutical company, has announced that the National...
Sino Medical Sciences Receives Hong Kong Approval for HT Supreme Drug-Eluting Stent System
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...
Hengrui Pharmaceuticals Gets NMPA Green Light for KRAS G12C Inhibitor Clinical Trial in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment
HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug...
ViiV Healthcare Presents Phase I Data for Ultra-Long-Acting Cabotegravir in HIV Treatment and Prevention
GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting...
Merck Teams Up with C4 Therapeutics for Targeted Protein Degraders in Oncology
Merck (NYSE: MRK), a Germany-headquartered science and technology company, has entered into a partnership with...
Innovent Biologics’ Taletrectinib Receives Second NDA Acceptance in China for ROS1 Positive NSCLC
Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that the...
BMS Reports Positive Long-Term Data for Zeposia in Multiple Sclerosis Trials
Bristol Myers Squibb (BMS; NYSE: BMY) has unveiled results from several Phase III trials for...
BeiGene’s Brukinsa Outperforms Acalabrutinib in MAIC for Relapsed/Refractory CLL, Says BeiGene
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the results of a matching-adjusted...
Merck’s Mavenclad Demonstrates Lasting Efficacy in RMS Patients, New Data Show
Merck KGaA (ETR: MRK), a German multinational pharmaceutical, chemical, and life sciences company, has this...
AlzeCure Pharma’s Alzheimer’s Drug Candidate ACD856 Receives Global Patent Awards
AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for...
Sino-Biocan Secures Series B Funding to Boost Cell and Gene Therapy Production Platforms
Sino-Biocan (Shanghai) Biotech Ltd, a provider of automated, modularized, closed cell production platforms for the...